IQVIA (IQV) Stock Forecast & Price Target

$190.99 +5.60 (+3.02%)

Closing price 08/22/2025 03:59 PM Eastern

Extended Trading

$190.02 -0.96 (-0.50%)

As of 08/22/2025 06:39 PM Eastern

IQVIA - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 23 Analyst Ratings

Sell
0

Hold
6

Buy
17

Based on 23 Wall Street analysts who have issued ratings for IQVIA in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 23 analysts, 6 have given a hold rating, and 17 have given a buy rating for IQV.

Consensus Price Target

$228.62
19.70% Upside

According to the 23 analysts' twelve-month price targets for IQVIA, the average price target is $228.62. The highest price target for IQV is $276.00, while the lowest price target for IQV is $160.00. The average price target represents a forecasted upside of 19.70% from the current price of $190.99.

Get the Latest News and Ratings for IQV and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for IQVIA and its competitors.

IQV Analyst Ratings Over Time

Type	Current Forecast 8/23/24 to 8/23/25	1 Month Ago 7/24/24 to 7/24/25	3 Months Ago 5/25/24 to 5/25/25	1 Year Ago 8/24/23 to 8/23/24
Strong Buy	0 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)
Buy	17 Buy rating(s)	17 Buy rating(s)	16 Buy rating(s)	12 Buy rating(s)
Hold	6 Hold rating(s)	7 Hold rating(s)	7 Hold rating(s)	4 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$228.62	$227.64	$226.32	$265.67
Forecasted Upside	19.70% Upside	13.22% Upside	65.24% Upside	6.72% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

IQV Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

IQV Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

IQVIA Stock vs. The Competition

Type	IQVIA	Medical Companies	S&P 500
Consensus Rating Score	2.74	2.79	2.53
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	19.70% Upside	13,202.85% Upside	9.65% Upside
News Sentiment Rating	Positive News See Recent IQV News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
7/25/2025	Mizuho 3 of 5 stars	Ann Hynes Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform ➝ Outperform	$190.00 ➝ $225.00	+13.90%
7/23/2025	Cowen 1 of 5 stars		Reiterated Rating	Buy ➝ Buy
7/23/2025	UBS Group 3 of 5 stars	Dan Leonard Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$185.00 ➝ $225.00	+15.70%
7/23/2025	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform
7/23/2025	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Jailendra Singh Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$209.00 ➝ $235.00	+22.12%
7/23/2025	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Luke Sergott Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Equal Weight ➝ Equal Weight	$165.00 ➝ $185.00	-1.54%
7/23/2025	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Eric Coldwell Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Neutral ➝ Neutral	$159.00 ➝ $196.00	+4.32%
7/9/2025	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Elizabeth Anderson Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform ➝ Outperform	$170.00 ➝ $180.00	+9.30%
5/23/2025	Redburn Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Jamie Clark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Target		$188.00	+37.26%
5/22/2025	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Neutral ➝ Neutral
Get the Latest News and Ratings for IQV and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for IQVIA and its competitors with MarketBeat's FREE daily newsletter.
5/19/2025	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Anne Samuel Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Overweight ➝ Overweight	$232.00 ➝ $177.00	+25.40%
4/25/2025	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Herholdt Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
4/25/2025	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Rajesh Kumar Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$260.00 ➝ $160.00	+6.17%
2/11/2025	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Tejas Savant Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$245.00 ➝ $250.00	+24.05%
2/10/2025	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Dodge Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$270.00 ➝ $270.00	+31.00%
2/7/2025	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Shlomo Rosenbaum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$273.00 ➝ $261.00	+24.95%
2/3/2025	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Larsen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
12/20/2024	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Garro Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$250.00	+30.53%
12/13/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$255.00 ➝ $235.00	+17.54%
11/19/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$260.00 ➝ $248.00	+28.58%
11/1/2024	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$270.00 ➝ $265.00	+27.09%
11/1/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$270.00 ➝ $255.00	+22.30%
11/1/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$280.00 ➝ $250.00	+20.00%
10/14/2024	Redburn Atlantic Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Clark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$276.00	+20.32%
7/31/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Toung Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/24/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold	$266.00 ➝ $242.00	+1.34%
2/26/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Davis Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
2/15/2024	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 04:38 PM ET.

Should I Buy IQVIA Stock? IQV Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, August 22, 2025. Please send any questions or comments about these IQVIA pros and cons to contact@marketbeat.com.

IQVIA
Bull Case

Here are some ways that investors could benefit from investing in IQVIA Holdings Inc.:

The current stock price is around $185, which reflects a strong market position and potential for growth in the medical research sector.
IQVIA Holdings Inc. reported a quarterly earnings per share (EPS) of $2.81, surpassing analyst expectations, indicating robust financial performance.
The company has shown a year-over-year revenue increase of 5.3%, suggesting a positive growth trajectory and resilience in its business model.
With a market capitalization of approximately $31.49 billion, IQVIA Holdings Inc. is well-positioned to leverage its resources for further expansion and innovation in analytics and technology solutions.
Institutional investors hold a significant 89.62% of the company's stock, reflecting strong confidence from major financial entities in the company's future prospects.

IQVIA
Bear Case

Investors should be bearish about investing in IQVIA Holdings Inc. for these reasons:

The company has a relatively high debt-to-equity ratio of 2.45, which may indicate potential financial risk and reliance on debt financing.
Insider trading activity shows a decrease in positions, with notable sales by insiders, which could signal a lack of confidence in the company's short-term performance.
Despite recent revenue growth, the company's quick and current ratios are both at 0.84, suggesting potential liquidity issues that could affect its ability to meet short-term obligations.
The price-to-earnings (P/E) ratio of 26.80 may indicate that the stock is overvalued compared to its earnings, which could deter value-focused investors.
Market volatility, as indicated by a beta of 1.30, suggests that the stock may experience larger fluctuations compared to the overall market, posing risks for conservative investors.

IQV Forecast - Frequently Asked Questions

: According to the research reports of 23 Wall Street equities research analysts, the average twelve-month stock price forecast for IQVIA is $228.62, with a high forecast of $276.00 and a low forecast of $160.00.
: 23 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for IQVIA in the last year. There are currently 6 hold ratings and 17 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" IQV shares.
: According to analysts, IQVIA's stock has a predicted upside of 19.70% based on their 12-month stock forecasts.
: IQVIA has been rated by research analysts at Barclays, Cowen, Evercore ISI, Mizuho, Robert W. Baird, Truist Financial, UBS Group, and William Blair in the past 90 days.
: Analysts like IQVIA less than other "medical" companies. The consensus rating score for IQVIA is 2.74 while the average consensus rating score for "medical" companies is 2.79. Learn more on how IQV compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NYSE:IQV) was last updated on 8/23/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

IQVIA (IQV) Stock Forecast & Price Target